Capmatinib is a pharmaceutical raw material that functions as a c-Met tyrosine kinase inhibitor. It is used in the manufacturing of research compounds for targeting cancers associated with MET gene mutations.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1029712-80-8
Capmatinib dihydrochloride monohydrate
pharmaceutical raw material
Zelboraf
pharmaceutical raw material
Trelagliptin succinate
pharmaceutical raw material
Paracetamol
pharmaceutical raw material
(R)-(7-METHYL-1,4-DIAZEPAN-1-YL)(5-METHYL-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE
pharmaceutical raw material
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
LIOLIMKSCNQPLV-UHFFFAOYSA-N
CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F